Sign In
Buy ZLDAF
$0.350
+0 (+0%)
At Close: Jun 02, 2026
Zelira Therapeutics (OTCMKTS:ZLDAF) and Hyperion DeFi (NASDAQ:HYPD) Critical Analysis
01:46am, Monday, 09'th Mar 2026
Hyperion DeFi (NASDAQ: HYPD - Get Free Report) and Zelira Therapeutics (OTCMKTS:ZLDAF - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies
Zelira secures transformative US$33 million funding for HOPE® 1 autism program
06:24am, Friday, 16'th Jan 2026
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) has secured a major funding milestone after its HOPE® 1 special purpose vehicle (SPV) signed definitive...
Zelira Therapeutics (OTCMKTS:ZLDAF) Trading Up 13.9% – Here’s Why
01:51am, Tuesday, 30'th Dec 2025
Shares of Zelira Therapeutics Limited (OTCMKTS:ZLDAF - Get Free Report) were up 13.9% during mid-day trading on Monday. The stock traded as high as $0.2660 and last traded at $0.2660. Approximately 17
Zelira Therapeutics (OTCMKTS:ZLDAF) Trading Down 4.4% – Here’s What Happened
01:52am, Thursday, 04'th Dec 2025
Zelira Therapeutics Limited (OTCMKTS:ZLDAF - Get Free Report)'s share price dropped 4.4% during mid-day trading on Wednesday. The stock traded as low as $0.2056 and last traded at $0.2056. Approximate
Zelira Therapeutics well placed to generate further growth in cash flow as commercialisation accelerates
11:30pm, Sunday, 30'th Jan 2022
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) is well placed to generate further growth in cash flow and revenue via its diversified income streams, with a suite of new products launched in H1 FY2022
Zelira Therapeutics receives A$1.292 million cash R&D tax incentive
07:18pm, Tuesday, 11'th Jan 2022
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) has received a cash refund of A$1.292 million under the Australian Federal Government's Research and Development Tax Incentive Scheme. The funds receiv
Zelira Therapeutics receives 25% of US$1 million licensing fee from DRCN Holdings for EDCDM technology
07:10pm, Sunday, 09'th Jan 2022
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) has received US$250,000 of its upfront non-refundable, non-contingent licensing fee of US$1 million from DRCN Holdings LLC, with the remaining US$750,000
Zelira Therapeutics' Phase 1 dose escalation study in chronic pain patients on long-term opioid treatment published in peer-reviewed journal
06:24pm, Wednesday, 22'nd Dec 2021
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF)'s open-label dose-escalation trial results in chronic non-cancer pain patients have been published in the peer-reviewed journal Pain And Therapy. The tri
Zelira Therapeutics expands into growing New Zealand cannabinoid-based medicines market
05:28pm, Wednesday, 15'th Dec 2021
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) is expanding into the growing New Zealand cannabinoid-based medicines market by way of a five-year exclusive distribution agreement with NUBU Pharmaceuti
Zelira Therapeutics gets ethics green light for Phase 2a trial of sports injury cannabinoid
06:22pm, Wednesday, 01'st Dec 2021
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), which develops clinically validated cannabis medications, has secured ethics approval for a Phase 2a clinical trial to assess the effectiveness of it
Zelira Therapeutics develops enhanced solid-form cannabinoid production method, signs foundational licensing deal
06:53pm, Tuesday, 02'nd Nov 2021
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) has opened new pathways to develop pharmaceutical-grade cannabidiol capsules and tablets with its proprietary Enhanced Distillate Capture and Dissolution
Zelira Therapeutics research-backed products behind its impressive growth
10:14pm, Thursday, 28'th Oct 2021
Zelira Therapeutics Ltd quarterly reads as a long list of highlights, which is testament to the work it is doing in the development of clinically validated cannabinoid medicines. The company has not o
Zelira Therapeutics gains substantial new US-based shareholder following US$5 million cap raise
08:19pm, Tuesday, 19'th Oct 2021
Zelira Therapeutics Ltd has raised a total of US$5 million from a US-based family office fund to accelerate its growth initiatives. Zelira is a global leader in the research and development of clinica
Zelira Therapeutics set to launch suite of new cannabinoid-based products over FY22 and grow sales of existing products
02:33am, Friday, 01'st Oct 2021
Zelira Therapeutics Ltd's research and development (R&D) and commercialisation programs are expected to lead to the launch of a suite of new cannabinoid-based products over FY22. In FY21, the global
Zelira™ Launches RAF FIVE™ Acne Treatment Products Through Its Dermatology Focused Subsidiary
08:09am, Thursday, 23'rd Sep 2021
PHILADELPHIA, Sept. 23, 2021 /PRNewswire/ -- Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF), a global leader in the research and development of clinically validated cannabinoid medicines, is plea
